A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
A phase 3 trial of Ibritumomab tiuxetan in Follicular lymphoma, run by Fondazione Italiana Linfomi - ETS, completed.
Overview
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) is a phase 3 interventional study registered as NCT01827605 by Fondazione Italiana Linfomi - ETS, with 159 participants recorded, started 2012-01 and reaching its primary completion in 2019-10. Interventions recorded: ZEVALIN, BEAM. Conditions recorded: Relapsed Follicular Lymphoma.
Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Follicular lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialIbritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
Shares Ibritumomab tiuxetan and the tag pipeline.
- TrialZevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Shares Ibritumomab tiuxetan and the tag pipeline.
- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Shares Follicular lymphoma and the tag pipeline.
- TrialMIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Shares Follicular lymphoma and the tag pipeline.
- TrialA Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Shares Follicular lymphoma and the tag pipeline.
- TrialDose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Shares Follicular lymphoma and the tag pipeline.
- TreatmentTC011
Shares Follicular lymphoma and the tag pipeline.
- TrialA Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
Shares Follicular lymphoma and the tag pipeline.